Craft
  • Home
  •  / Keros Therapeutics
Keros Therapeutics

Keros Therapeutics

Revenue

$20.1 M

FY, 2021

Market Capitalization

$862.7 M

2022-09-20

Keros Therapeutics Summary

Company summary

Overview
Keros Therapeutics is a biotechnology company dedicated to the discovery and development of therapeutics for hematological and musculoskeletal disorders. Its lead protein therapeutic product candidate, KER-050, is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. Keros Therapeutics' small molecule product candidate, KER-047, is designed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva. The company also develops KER-01, a preclinical protein therapeutic product candidate that is designed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
Type
Public
Founded
2015
HQ
Lexington, MA, US | view all locations
Website
http://kerostx.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Jasbir Seehra
  • Jennifer Lachey

    Jennifer Lachey, Chief Scientific Officer

  • Claudia Ordonez

    Claudia Ordonez, Chief Medical Officer

  • Keith Regnante

    Keith Regnante, Chief Financial Officer

LocationsView all

1 location detected

  • Lexington, MA HQ

    United States

    99 Hayden Ave suite 120 building e

Keros Therapeutics Financials

Summary financials

Net income (Q2, 2022)
($27.3M)
Cash (Q2, 2022)
$215.6M
EBIT (Q2, 2022)
($30.7M)
Enterprise value
$647.8M

Footer menu